Meixiang Sang

3.2k total citations · 1 hit paper
107 papers, 2.4k citations indexed

About

Meixiang Sang is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Meixiang Sang has authored 107 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Molecular Biology, 42 papers in Cancer Research and 38 papers in Oncology. Recurrent topics in Meixiang Sang's work include MicroRNA in disease regulation (32 papers), Circular RNAs in diseases (29 papers) and Immunotherapy and Immune Responses (25 papers). Meixiang Sang is often cited by papers focused on MicroRNA in disease regulation (32 papers), Circular RNAs in diseases (29 papers) and Immunotherapy and Immune Responses (25 papers). Meixiang Sang collaborates with scholars based in China, Japan and United States. Meixiang Sang's co-authors include Lina Gu, Lingjiao Meng, Baoen Shan, Yishui Lian, Cuizhi Geng, Fei Liu, Ping’an Ding, Xinliang Zhou, Sihua Liu and Baoen Shan and has published in prestigious journals such as Cancer Research, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Meixiang Sang

102 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks

2024 82 citations Lingjiao Meng, Ping’an Ding et al. Cell Death and Disease profile →

Peers

Meixiang Sang

ONCOL

IMMUN

PRM

Farhad Vesuna United States

Nako Maishi Japan

Alicia S. Chung United States

Xueman Chen China

Christos K. Kontos Greece

Elena Levantini United States

Joseph Kwong Hong Kong

Oskar W. Rokhlin United States

Yu‐Ting Chou Taiwan

Dan Liao China

Farhad Vesuna United States

Meixiang Sang

1.7k ×1.0

708 ×0.7

1.1k ×1.5

ONCOL

273 ×0.5

IMMUN

213 ×0.9

PRM

Citations per year, relative to Meixiang Sang Meixiang Sang (= 1×) peers Farhad Vesuna

Countries citing papers authored by Meixiang Sang

Since Specialization

Citations

This map shows the geographic impact of Meixiang Sang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meixiang Sang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meixiang Sang more than expected).

Fields of papers citing papers by Meixiang Sang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meixiang Sang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meixiang Sang. The network helps show where Meixiang Sang may publish in the future.

Co-authorship network of co-authors of Meixiang Sang

This figure shows the co-authorship network connecting the top 25 collaborators of Meixiang Sang. A scholar is included among the top collaborators of Meixiang Sang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meixiang Sang. Meixiang Sang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ding, Ping’an, et al.. (2025). Aberrant CircTMEM45A Facilitates Inflammatory Progression of Esophageal Squamous Cell Carcinoma through m5C-Mediated NLRP3 Activation. Cancer Research. 85(14). 2694–2713. 3 indexed citations

Wu, Lixia, Lina Gu, Yang Zheng, et al.. (2025). CircPRKCA facilitates esophageal squamous cell carcinoma metastasis via m5C-dependent CSF2 mRNA stabilization. Journal of Translational Medicine. 23(1). 385–385. 2 indexed citations

Liu, Jingjing, Lingjiao Meng, Lixia Wu, et al.. (2024). CircJPH1 regulates the NF-κB/HERC5 axis to promote the malignant progression of esophageal squamous cell carcinoma through binding to XRCC6. Cellular Signalling. 124. 111403–111403. 1 indexed citations

Li, Sainan, Huimin Wang, Xuejiao Ma, et al.. (2023). An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer. The Oncologist. 28(12). e1160–e1169. 4 indexed citations

Ding, Ping’an, Ziyi Li, Fei Liu, et al.. (2023). Circular RNA circ‐TNRC6B inhibits the proliferation and invasion of esophageal squamous cell carcinoma cells by regulating the miR‐452‐5p/DAG1 axis. Molecular Oncology. 17(7). 1437–1452. 11 indexed citations

Li, Sainan, Jiajie Shi, Meng Cheng, et al.. (2023). KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy. International Journal of General Medicine. Volume 16. 3623–3635.

Cao, Feng, Sihua Liu, Ziyi Li, et al.. (2022). Activation of circ_0072088/miR‐1261/PIK3CA pathway accelerates lung adenocarcinoma progression. Thoracic Cancer. 13(11). 1548–1557. 9 indexed citations

Duan, Yuqing, Jiali Wang, Tianxu Liu, et al.. (2021). Long noncoding RNA DGCR5 involves in tumorigenesis of esophageal squamous cell carcinoma via SRSF1-mediated alternative splicing of Mcl-1. Cell Death and Disease. 12(6). 587–587. 34 indexed citations

Li, Juan, Meixiang Sang, Yang Zheng, et al.. (2021). HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2. Experimental Cell Research. 409(1). 112891–112891. 11 indexed citations

10.

Meng, Lingjiao, Sihua Liu, Fei Liu, et al.. (2020). ZEB1-Mediated Transcriptional Upregulation of circWWC3 Promotes Breast Cancer Progression through Activating Ras Signaling Pathway. Molecular Therapy — Nucleic Acids. 22. 124–137. 36 indexed citations

11.

Li, Sainan, Shan Yang, Jiajie Shi, et al.. (2020). Recognition of the organ-specific mutations in metastatic breast cancer by circulating tumor cells isolated in vivo.. Neoplasma. 68(1). 31–39. 6 indexed citations

12.

Gu, Lina, Meixiang Sang, Fei Liu, et al.. (2019). Expression and prognostic significance of MAGE-A11 and transcription factors (SP1,TFCP2 and ZEB1) in ESCC tissues. Pathology - Research and Practice. 215(7). 152446–152446. 13 indexed citations

13.

Sang, Meixiang, Lingjiao Meng, Sihua Liu, et al.. (2018). Circular RNA ciRS-7 Maintains Metastatic Phenotypes as a ceRNA of miR-1299 to Target MMPs. Molecular Cancer Research. 16(11). 1665–1675. 73 indexed citations

14.

Sang, Meixiang, Cuicui Ma, Sihua Liu, et al.. (2018). Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction. Biomedicine & Pharmacotherapy. 111. 169–177. 8 indexed citations

15.

Zhou, Xinliang, Jing Han, Zhisong Fan, et al.. (2018). miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer. Cancer Gene Therapy. 25(3-4). 68–76. 71 indexed citations

16.

Liu, F., et al.. (2018). Tumor suppressor let-7a inhibits breast cancer cell proliferation, migration and invasion by targeting MAGE-A1. Neoplasma. 66(1). 54–62. 20 indexed citations

17.

Sang, Meixiang, Lina Gu, Fei Liu, et al.. (2016). MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma: a retrospective clinical study based on tissue microarray. Journal of Clinical Pathology. 70(6). 533–540. 25 indexed citations

18.

Liu, Fei, Lina Gu, Baoen Shan, Cuizhi Geng, & Meixiang Sang. (2016). Biomarkers for EMT and MET in breast cancer: An update. Oncology Letters. 12(6). 4869–4876. 99 indexed citations

19.

Zhou, Xinliang, Meixiang Sang, Wei Liu, et al.. (2012). LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53. Life Sciences. 91(9-10). 358–363. 15 indexed citations

20.

Sang, Meixiang, et al.. (2009). Effect of melanoma antigen MAGE-A4 on the transcriptional activity of p53.. Tumori. 29(5). 428–432. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact